Adults with obesity have been shown to have both gut dysbiosis and changes in the BA pool composition, leading to the initiation of clinical trials to test microbiome-based treatments (e.g., fecal microbiota transplantation) and BA-based treatments (e.g., FXR agonists) to manage obesity and related conditions [reviewed in (44)]. This evidence concerns the gene NR1H4 and Obesity.